The size of the Global Pancreatic Cancer Therapeutics Market was worth USD 2.41 billion in 2019 and estimated to be growing at a CAGR of 7.54%, to reach USD 3.47 billion by 2024 during the forecast period 2019 - 2024.
Pancreatic cancer is caused by the uncontrolled growth of cells in the pancreas. This abnormal, unrestrained growth of cells results in the formation of lumps of tissue, widely referred to as tumors. The presence of tumors prevents the normal functioning of the pancreas. The occurrence and mortality rate of pancreatic cancer is more in men than in women. SEER estimates that pancreatic cancer accounts for around seven percent of the total cancer deaths in the US annually.
Cancer starts when cells in the body begin to grow beyond control. Pancreatic cancer starts when cells in the pancreas start to grow incessantly eventually resulting in symptoms like abdominal pain, weight loss, diarrhea, and jaundice. The developed tumor hinders the normal functioning of the pancreas. The biggest risk factor which leads to pancreatic cancer is smoking. Apart from lifestyle dependent factors like alcohol consumption, obesity and smoking, a personal or family history of pancreatitis or old age may result in a person being affected by pancreatic cancer.
Having less than five-year survival, the pancreatic cancer market has one of the highest unmet therapeutic needs in the oncology market across the globe. Clearly, this is also the most challenging aspect that this market needs to address. Given the insuppressibly nature of pancreatic cancer, treatments often return insufficient results. This challenge is yet another barrier to the growth of this market. Technologies are yet to develop fully for the timely diagnosis of this cancer type, which results in the diagnosis of the majority of pancreatic cancer patients at an advanced stage of the disease. This explains the high mortality rates associated with pancreatic cancer. Estimates show that only a small percentage, that is about 12% to 15% of the patients is diagnosed early enough to be treated with surgical procedures, drugs, and chemotherapy.
Market Size Available
2018 – 2024
2019 - 2024
By Type, Treatment Type, End Users and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, APAC, Latin America, Middle East & Africa
Market Leaders Profiled
Eli Lilly, Amgen Inc., Celgene Corp., F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Novartis AG, Threshold Pharmaceuticals Inc., Aduro BioTech Inc., Infinity Pharmaceuticals Inc. and NewLink Genetics Corp.
This research report on the Global Pancreatic Cancer Therapeutics Market segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2024.
Pancreatic Cancer Therapeutics Market Analysis - By Cancer Type:
Pancreatic Cancer Therapeutics Market Analysis - By Treatment Type:
Pancreatic Cancer Therapeutics Market Analysis - By End User:
On the basis of end-user, the Hospital segment is the significant revenue-generating segment in the global pancreatic cancer therapeutics market, which are supposed to continue further in the forecast years.
Globally, North America is the largest market for pancreatic cancer. The prevalence of pancreatic cancer is more in North American countries with the U.S. having the highest number of pancreatic cancer patients in the world. Europe is expected to be the second-largest market for pancreatic cancer. Asia-Pacific is anticipated to be the fastest-growing region across the globe.
List of companies leading the Global Pancreatic Cancer Therapeutics Market profiled in the report are:
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type of Treatment
5.1.4 Radiation Therapy
5.1.6 Y-o-Y Growth Analysis, By Type of Treatment
5.1.7 Market Attractiveness Analysis, By Type of Treatment
5.1.8 Market Share Analysis, By Type of Treatment
5.2.2 Exocrine Pancreas Cancer
5.2.3 Endocrine Pancreas Cancer
5.2.4 Y-o-Y Growth Analysis, By Type
5.2.5 Market Attractiveness Analysis, By Type
5.2.6 Market Share Analysis, By Type
5.3.4 Research Institutes
5.3.6 Y-o-Y Growth Analysis, By End-users
5.3.7 Market Attractiveness Analysis, By End-users
5.3.8 Market Share Analysis, By End-users
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Type of Treatment
188.8.131.52 By Type
184.108.40.206 By End-users
6.1.4 Market Attractiveness Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Type of Treatment
22.214.171.124 By Type
126.96.36.199 By End-users
6.1.5 Market Share Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Type of Treatment
220.127.116.11 By Type
18.104.22.168 By End-users
6.2 North America
6.1.2 United States
6.3.6 South Korea
6.5 Latin America
6.4.5 Rest of Latin America
6.6 Middle East & Africa
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Eli Lilly
8.1.2 Type of Product
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Amgen, Inc.
8.3 Celgene Corp.
8.4 F. Hoffmann-La Roche
8.5 Clovis Oncology Inc.
8.7 Novartis AG
8.8 Threshold Pharmaceuticals Inc.
8.9 Aduro BioTech Inc.
8.10 Infinity Pharmaceuticals Inc.
8.11 NewLink Genetics Corp.
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures